Clinical Trials: Pilot Study of Redirected Autologous t Cells Engineered to Contain Anti-cd19 Attached to tcrζ and 4-1bb Signaling Domains in Patients With Chemotherapy Resistant or Refractory cd19+ Leukemia and Lymphoma

Share this content:

Sponsor and Collaborators

University of Pennsylvania

Lentigen Corporation

Contact

David Porter, MD

trpctu@mail.med.upenn.edu

Principal Investigator

David Porter, MD, University of Pennsylvania

ClinicalTrials.gov Identifier

NCT00891215

Loading links....

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs